A Comparison: LABA/ICS vs LABA/LAMA. In a 52-week trial, 3360 patients with moderate-to-severe COPD received either the twice-daily fixed-dose combination of salmeterol and fluticasone or the once ...

Using our insurer’s formulary as an example, ... have a lower average wholesale price. 13 The LAMA/LABA inhaler and ICS inhaler combination would also simplify future step-down to dual ...

Among patients with COPD who complain of dyspnea or exercise intolerance, we recommend LABA/LAMA combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence).

An inhaler combining a long-acting muscarinic antagonist (LAMA) with a long-acting beta 2-agonist (LABA) has been FDA-approved for maintenance treatment of airflow obstruction in patients with ...

There are currently a number of LABA/LAMA fixed-dose combinations in development for COPD. 28 QVA149 (an inhaled fixed-dose combination comprising two 24-hr agents, the LABA indacaterol and the ...

6 August2012, USA California (Acedrugstore.com): An experimental and novel lung medication with is a combination drug of LAMA/LABA and produced by GlaxoSmithKline and Theravance pharmaceutical compani ...

GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III ...

SAN DIEGO — Patients who received a free or fixed-dose combination of a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) experienced a lower risk for chronic ...

LAMA-LABA inhaler combinations used by patients in this study included aclidinium-formoterol (Duaklir Pressair, Covis), glycopyrronium-formoterol (Bevespi Aerosphere, ...

Data comparing the incidence of severe adverse events among different LAMA/LABA combinations are lacking, they said. In a study published in the journal Chest, the researchers reviewed claims data ...

GlaxoSmithKline said on Monday its experimental once-daily lung drug LAMA/LABA showed positive results in four late-stage trials in patients with chronic obstructive pulmonary disease (COPD).

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. Cerebrovascular event frequency was 0.42% for LABA ...